{
  "ProtocolSection": {
    "IdentificationModule": {
      "NCTId": "NCT02675556",
      "OrgStudyIdInfo": {
        "OrgStudyId": "20140917"
      },
      "Organization": {
        "OrgFullName": "University of Miami",
        "OrgClass": "OTHER"
      },
      "BriefTitle": "Allogeneic Human Mesenchymal Stem Cells (hMSCs) Infusion in Patients With Treatment Resistant Depression",
      "OfficialTitle": "A Phase I, Prospective, Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Safety and Potential Efficacy of Allogeneic Human Mesenchymal Stem Cell Infusion Versus Placebo in Patients With Treatment Resistant Depression.",
      "Acronym": "ANU"
    },
    "StatusModule": {
      "StatusVerifiedDate": "March 2019",
      "OverallStatus": "Terminated",
      "WhyStopped": "Difficulty in recruitment and funding.",
      "ExpandedAccessInfo": {
        "HasExpandedAccess": "No"
      },
      "StartDateStruct": {
        "StartDate": "October 31, 2017",
        "StartDateType": "Actual"
      },
      "PrimaryCompletionDateStruct": {
        "PrimaryCompletionDate": "March 26, 2019",
        "PrimaryCompletionDateType": "Actual"
      },
      "CompletionDateStruct": {
        "CompletionDate": "March 26, 2019",
        "CompletionDateType": "Actual"
      },
      "StudyFirstSubmitDate": "February 1, 2016",
      "StudyFirstSubmitQCDate": "February 3, 2016",
      "StudyFirstPostDateStruct": {
        "StudyFirstPostDate": "February 5, 2016",
        "StudyFirstPostDateType": "Estimate"
      },
      "LastUpdateSubmitDate": "March 28, 2019",
      "LastUpdatePostDateStruct": {
        "LastUpdatePostDate": "April 1, 2019",
        "LastUpdatePostDateType": "Actual"
      }
    },
    "SponsorCollaboratorsModule": {
      "ResponsibleParty": {
        "ResponsiblePartyType": "Sponsor-Investigator",
        "ResponsiblePartyInvestigatorFullName": "Joshua M Hare",
        "ResponsiblePartyInvestigatorTitle": "Sponsor - Investigator",
        "ResponsiblePartyInvestigatorAffiliation": "University of Miami"
      },
      "LeadSponsor": {
        "LeadSponsorName": "Joshua M Hare",
        "LeadSponsorClass": "OTHER"
      }
    },
    "OversightModule": {
      "OversightHasDMC": "Yes",
      "IsFDARegulatedDrug": "Yes",
      "IsFDARegulatedDevice": "No"
    },
    "DescriptionModule": {
      "BriefSummary": "This study is intended to evaluate the safety and potential efficacy of Allogeneic Human Mesenchymal Stem Cell Infusion versus placebo in patients with Treatment Resistant Depression.",
      "DetailedDescription": "This is a phase I study, with eight subjects in the pilot phase and eighty (80) subjects fulfilling all inclusion/exclusion criteria's will be randomly assigned to receive allogeneic Human Mesenchymal Stem Cell (hMSCs) or placebo in a 1:1 blinded fashion.\n\nThe 8 subjects in the pilot phase will receive a single infusion of 100 million hMSCs.\n\n40 patients will receive a single administration of allogeneic hMSCs and another 40 patients will receive a single administration of Placebo in a 1:1 blinded fashion.\n\nFollowing infusion, patients will be followed at 2, 4, 6, 8, 10 and 12 week's post-infusion to complete all safety and efficacy assessments. During these 12 weeks starting after the week 2 visit subjects will have a phone call in-between their visits. Patients will additionally be followed for up to 12 months post-infusion."
    },
    "ConditionsModule": {
      "ConditionList": {
        "Condition": [
          "Treatment Resistant Depression"
        ]
      },
      "KeywordList": {
        "Keyword": [
          "Depression"
        ]
      }
    },
    "DesignModule": {
      "StudyType": "Interventional",
      "PhaseList": {
        "Phase": [
          "Phase 1"
        ]
      },
      "DesignInfo": {
        "DesignAllocation": "Randomized",
        "DesignInterventionModel": "Parallel Assignment",
        "DesignPrimaryPurpose": "Treatment",
        "DesignMaskingInfo": {
          "DesignMasking": "Triple",
          "DesignWhoMaskedList": {
            "DesignWhoMasked": [
              "Participant",
              "Care Provider",
              "Investigator"
            ]
          }
        }
      },
      "EnrollmentInfo": {
        "EnrollmentCount": "1",
        "EnrollmentType": "Actual"
      }
    },
    "ArmsInterventionsModule": {
      "ArmGroupList": {
        "ArmGroup": [
          {
            "ArmGroupLabel": "Allogeneic hMSCs",
            "ArmGroupType": "Experimental",
            "ArmGroupDescription": "Forty (40) subjects will be treated with a single administration of allogeneic Human Mesenchymal Stem Cell (hMSCs): 100 x 10^6 (100 million) allo-hMSCs of cells delivered via a single peripheral intravenous infusion.",
            "ArmGroupInterventionList": {
              "ArmGroupInterventionName": [
                "Drug: Allo-hMSCs"
              ]
            }
          },
          {
            "ArmGroupLabel": "Placebo",
            "ArmGroupType": "Placebo Comparator",
            "ArmGroupDescription": "Forty (40) subjects will be treated with a placebo administration consisting of 1% human albumin serum in Plasma-Lyte A delivered via a single peripheral intravenous infusion.",
            "ArmGroupInterventionList": {
              "ArmGroupInterventionName": [
                "Drug: Placebo"
              ]
            }
          },
          {
            "ArmGroupLabel": "Pilot - Allogeneic hMSCs",
            "ArmGroupType": "Experimental",
            "ArmGroupDescription": "Eight (8) subjects will be treated with a single administration of allogeneic Human Mesenchymal Stem Cell (hMSCs): 100 x 10^6 (100 million) allo-hMSCs of cells delivered via a single peripheral intravenous infusion.",
            "ArmGroupInterventionList": {
              "ArmGroupInterventionName": [
                "Drug: Allo-hMSCs"
              ]
            }
          }
        ]
      },
      "InterventionList": {
        "Intervention": [
          {
            "InterventionType": "Drug",
            "InterventionName": "Allo-hMSCs",
            "InterventionDescription": "a single administration of allogeneic Human Mesenchymal Stem Cell (hMSCs): 100 x 10^6 (100 million) allo-hMSCs of cells",
            "InterventionArmGroupLabelList": {
              "InterventionArmGroupLabel": [
                "Allogeneic hMSCs",
                "Pilot - Allogeneic hMSCs"
              ]
            },
            "InterventionOtherNameList": {
              "InterventionOtherName": [
                "Allogeneic Human Mesenchymal Stem Cells",
                "Stem Cells"
              ]
            }
          },
          {
            "InterventionType": "Drug",
            "InterventionName": "Placebo",
            "InterventionDescription": "a placebo administration consisting of 1% human albumin serum in Plasma-Lyte A",
            "InterventionArmGroupLabelList": {
              "InterventionArmGroupLabel": [
                "Placebo"
              ]
            }
          }
        ]
      }
    },
    "OutcomesModule": {
      "PrimaryOutcomeList": {
        "PrimaryOutcome": [
          {
            "PrimaryOutcomeMeasure": "Incidence of any treatment-emergent serious adverse events (TE-SAEs)",
            "PrimaryOutcomeDescription": "defined as a composite of acute suicidality, and hospitalization for suicide attempts.",
            "PrimaryOutcomeTimeFrame": "One month post infusion"
          }
        ]
      },
      "SecondaryOutcomeList": {
        "SecondaryOutcome": [
          {
            "SecondaryOutcomeMeasure": "Reduction of Inflammation",
            "SecondaryOutcomeDescription": "Reduction of Inflammation: Change in serum concentrations of high sensitivity C-Reactive Protein (hs-CRP)",
            "SecondaryOutcomeTimeFrame": "Week 12"
          }
        ]
      },
      "OtherOutcomeList": {
        "OtherOutcome": [
          {
            "OtherOutcomeMeasure": "Reductions in serum concentrations",
            "OtherOutcomeDescription": "Reductions in serum concentrations of other inflammatory markers;",
            "OtherOutcomeTimeFrame": "Week 12"
          },
          {
            "OtherOutcomeMeasure": "Reduction in Depressive Symptoms",
            "OtherOutcomeDescription": "Reduction in Depressive Symptoms due to change in Montgomery-Asberg Depression Rating Scale (MADRS)",
            "OtherOutcomeTimeFrame": "Week 12"
          },
          {
            "OtherOutcomeMeasure": "Reduction in Anhedonia",
            "OtherOutcomeDescription": "Reduction in Anhedonia due to change in the Snaith Hamilton Pleasure Scale",
            "OtherOutcomeTimeFrame": "Week 12"
          },
          {
            "OtherOutcomeMeasure": "Improvements in Cognition",
            "OtherOutcomeDescription": "Improvements in Cognition as a result of changes in Brief Assessment of Cognition for Affective Disorders (BAC-A), Performance Based Skills Assessment (UPSA-B), and Specific Level of Functioning (SLOF) scores",
            "OtherOutcomeTimeFrame": "Week 12"
          },
          {
            "OtherOutcomeMeasure": "Improvements in Functional Capacity",
            "OtherOutcomeDescription": "Improvements in Functional Capacity as a result of changes in Brief Assessment of Cognition for Affective Disorders (BAC-A), Performance Based Skills Assessment (UPSA-B), and Specific Level of Functioning (SLOF) scores",
            "OtherOutcomeTimeFrame": "Week 12"
          },
          {
            "OtherOutcomeMeasure": "Improvements in everyday functioning",
            "OtherOutcomeDescription": "Improvements in everyday functioning as a result of changes in Brief Assessment of Cognition for Affective Disorders (BAC-A), Performance Based Skills Assessment (UPSA-B), and Specific Level of Functioning (SLOF) scores",
            "OtherOutcomeTimeFrame": "Week 12"
          },
          {
            "OtherOutcomeMeasure": "Mediating effects of child abuse and neglect.",
            "OtherOutcomeDescription": "Mediating effects of child abuse and neglect.",
            "OtherOutcomeTimeFrame": "week 12"
          }
        ]
      }
    },
    "EligibilityModule": {
      "EligibilityCriteria": "Inclusion Criteria:\n\nProvide written informed consent.\nSubjects age equal or greater than 18 and equal or less than 75 years at the time of signing the Informed Consent Form.\nDiagnosis of Treatment resistant depression (Failed at least two adequate trials of antidepressant monotherapy or antidepressant augmentation with an antipsychotic or lithium during the current episode)\nPatients who are receiving a third or more treatment will only be entered if they have not responded to the current treatment.\nExperiencing a current Major Depressive Episode (fulfilling Structured clinical interview for Diagnostic and Statistical Manual of Mental Disorders (DSM V) criteria per Structured Clinical Interview for DSM (SCID) for categorical diagnosis, and the Hamilton Depression Rating Scale for Depression (HAM-D))\nHamilton Depression Rating Scale 21-item score greater than 18\nAdequacy of previous failed antidepressant trials will be defined using standard criteria by Massachusetts General Hospital (MGH) of patients with a score greater than or equal to 2.5\nIncreased inflammation ([Serum CRP] greater than 3.0 mg/L)\n\nExclusion Criteria:\n\nIn order to participate in this study, a patient Must Not:\n\nWomen who are pregnant, nursing, or of childbearing potential, while not practicing effective contraceptive methods. (Female subjects of childbearing potential must undergo a serum or urine pregnancy test at screening and within 36 hours prior to infusion.)\nInability to perform any of the assessments required.\nHave clinically significant abnormal screening laboratory values, including but not limited to: hemoglobin <8 g/dl, white blood cell count <3000/mm3, platelets<80,000/mm3, INR > 1.5 not due to a reversible cause (i.e. Coumadin), aspartate transaminase, alanine transaminase, or alkaline phosphatase > 3 times upper limit of normal, total bilirubin > 1.8 mg/dl (unless due to a benign cause).\nActive medical condition that could cause or exacerbate depressive symptoms (e.g., hypothyroidism, anemia)\nSerious comorbid illness or any other condition (Such as bipolar, schizophrenia or schizoaffective disorder) that, in the opinion of the investigator, may compromise the safety or compliance of the subject or preclude successful completion of the study.\nHave acute suicidality\nPrior history of a suicide attempt, within the past year.\nActive psychotic disorder, eating disorder, or substance use disorder within 6 months of enrollment\nTreatment with any medication that, in the opinion of the Investigator, may compromise the safety of the subject or affect the validity of the data or the study endpoints.\nFirst major depressive episode after 50 years of age.\nHave known allergies to penicillin or streptomycin.\nHave hypersensitivity to dimethyl sulfoxide (DMSO).\nHave a clinical history of malignancy within 5 years (i.e., subjects with prior malignancy must be disease free for 5 years), except curatively-treated basal cell carcinoma, squamous cell carcinoma, melanoma in situ or cervical carcinoma.\nHave a non-pulmonary condition that limits lifespan to < 1 year.\nHave a history of drug or alcohol abuse within the past 24 months.\nBe serum positive for HIV, hepatitis BsAg or Viremic hepatitis C.",
      "HealthyVolunteers": "No",
      "Gender": "All",
      "MinimumAge": "18 Years",
      "MaximumAge": "75 Years",
      "StdAgeList": {
        "StdAge": [
          "Adult",
          "Older Adult"
        ]
      }
    },
    "ContactsLocationsModule": {
      "OverallOfficialList": {
        "OverallOfficial": [
          {
            "OverallOfficialName": "Joshua M Hare, MD",
            "OverallOfficialAffiliation": "ISCI / University of Miami Miller School of Medicine",
            "OverallOfficialRole": "Study Director"
          }
        ]
      },
      "LocationList": {
        "Location": [
          {
            "LocationFacility": "University of Miami Miller School of Medicine",
            "LocationCity": "Miami",
            "LocationState": "Florida",
            "LocationZip": "33136",
            "LocationCountry": "United States"
          }
        ]
      }
    },
    "IPDSharingStatementModule": {
      "IPDSharing": "Undecided"
    }
  },
  "DerivedSection": {
    "MiscInfoModule": {
      "VersionHolder": "January 20, 2022"
    },
    "ConditionBrowseModule": {
      "ConditionMeshList": {
        "ConditionMesh": [
          {
            "ConditionMeshId": "D000003863",
            "ConditionMeshTerm": "Depression"
          },
          {
            "ConditionMeshId": "D000003866",
            "ConditionMeshTerm": "Depressive Disorder"
          },
          {
            "ConditionMeshId": "D000061218",
            "ConditionMeshTerm": "Depressive Disorder, Treatment-Resistant"
          }
        ]
      },
      "ConditionAncestorList": {
        "ConditionAncestor": [
          {
            "ConditionAncestorId": "D000001526",
            "ConditionAncestorTerm": "Behavioral Symptoms"
          },
          {
            "ConditionAncestorId": "D000019964",
            "ConditionAncestorTerm": "Mood Disorders"
          },
          {
            "ConditionAncestorId": "D000001523",
            "ConditionAncestorTerm": "Mental Disorders"
          }
        ]
      },
      "ConditionBrowseLeafList": {
        "ConditionBrowseLeaf": [
          {
            "ConditionBrowseLeafId": "M6210",
            "ConditionBrowseLeafName": "Depression",
            "ConditionBrowseLeafAsFound": "Depression",
            "ConditionBrowseLeafRelevance": "high"
          },
          {
            "ConditionBrowseLeafId": "M6213",
            "ConditionBrowseLeafName": "Depressive Disorder",
            "ConditionBrowseLeafAsFound": "Depression",
            "ConditionBrowseLeafRelevance": "high"
          },
          {
            "ConditionBrowseLeafId": "M28936",
            "ConditionBrowseLeafName": "Depressive Disorder, Treatment-Resistant",
            "ConditionBrowseLeafAsFound": "Treatment Resistant Depression",
            "ConditionBrowseLeafRelevance": "high"
          },
          {
            "ConditionBrowseLeafId": "M3970",
            "ConditionBrowseLeafName": "Behavioral Symptoms",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "M20988",
            "ConditionBrowseLeafName": "Mood Disorders",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "M3967",
            "ConditionBrowseLeafName": "Mental Disorders",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "M13625",
            "ConditionBrowseLeafName": "Psychotic Disorders",
            "ConditionBrowseLeafRelevance": "low"
          }
        ]
      },
      "ConditionBrowseBranchList": {
        "ConditionBrowseBranch": [
          {
            "ConditionBrowseBranchAbbrev": "BXM",
            "ConditionBrowseBranchName": "Behaviors and Mental Disorders"
          },
          {
            "ConditionBrowseBranchAbbrev": "All",
            "ConditionBrowseBranchName": "All Conditions"
          }
        ]
      }
    },
    "InterventionBrowseModule": {
      "InterventionBrowseLeafList": {
        "InterventionBrowseLeaf": [
          {
            "InterventionBrowseLeafId": "M85407",
            "InterventionBrowseLeafName": "Plasma-lyte 148",
            "InterventionBrowseLeafRelevance": "low"
          }
        ]
      },
      "InterventionBrowseBranchList": {
        "InterventionBrowseBranch": [
          {
            "InterventionBrowseBranchAbbrev": "PhSol",
            "InterventionBrowseBranchName": "Pharmaceutical Solutions"
          },
          {
            "InterventionBrowseBranchAbbrev": "All",
            "InterventionBrowseBranchName": "All Drugs and Chemicals"
          }
        ]
      }
    }
  }
}